Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) was the recipient of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,450,000 shares, a decrease of 17.1% from the November 15th total of 1,750,000 shares. Based on an average daily volume of 1,300,000 shares, the short-interest ratio is presently 1.1 days. Currently, 1.7% of the company’s stock are sold short.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Craig Hallum boosted their price target on Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC boosted their target price on shares of Cellebrite DI from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday. Finally, TD Cowen upped their price objective on Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $20.57.
Check Out Our Latest Report on CLBT
Cellebrite DI Stock Up 2.1 %
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.05. The firm had revenue of $106.90 million for the quarter, compared to analysts’ expectations of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.09 EPS. As a group, equities analysts predict that Cellebrite DI will post 0.32 earnings per share for the current fiscal year.
Institutional Trading of Cellebrite DI
Institutional investors have recently bought and sold shares of the business. FMR LLC grew its holdings in shares of Cellebrite DI by 136.3% during the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company’s stock worth $94,586,000 after purchasing an additional 3,239,307 shares in the last quarter. Principal Financial Group Inc. bought a new stake in Cellebrite DI during the third quarter worth about $23,402,000. Pembroke Management LTD grew its stake in Cellebrite DI by 104.9% during the second quarter. Pembroke Management LTD now owns 1,535,726 shares of the company’s stock worth $18,352,000 after buying an additional 786,310 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in Cellebrite DI in the 3rd quarter valued at about $11,523,000. Finally, Summit Partners Public Asset Management LLC acquired a new position in shares of Cellebrite DI in the 3rd quarter valued at approximately $9,274,000. Institutional investors own 45.88% of the company’s stock.
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
- Five stocks we like better than Cellebrite DI
- The How and Why of Investing in Gold Stocks
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- Financial Services Stocks Investing
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- What Investors Need to Know About Upcoming IPOs
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.